Matthew S. Block

Matthew S. Block

Auto-generated profile, based on publicly available information

Matthew S. Block

Department of Oncology, Mayo Clinic, Rochester, MN, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
SWSimrit K. Warring
Simrit K. Warring
KPKah-Whye Peng
Kah-Whye Peng
PAPamela J. Atherton
Pamela J. Atherton
EAErik J. Asmus
Erik J. Asmus
LZLianwen Zhang
Lianwen Zhang
JBJamie N. Bakkum-Gamez
Jamie N. Bakkum-Gamez
Oncolytic virotherapy combines direct tumor cell lysis with immune activation to generate antitumor T-cell responses. We report results from a phase I trial of intravenous (IV) vesicular stomatitis virus expressing human interferon-β and the sodium iodide symporter (VSV-hIFNβ-NIS) in patients with stage IV or recurrent endometrial cancer (EC).Patients with stage IV or recurrent EC (largest tumor ≤5 cm) received a single IV infusion of VSV-hIFNβ-NIS in a 3+3 dose-escalation trial. Five dose levels (5×10⁹–3.5×10¹¹ TCID₅₀) were planned. The primary endpoint was maximum tolerated dose (MTD). Secondary endpoints included pharmacokinetics, pharmacodynamics, RECIST v1.1 response, and exploratory immune correlates. Tumor assessment was performed on day 29. A post hoc analysis evaluated durable clinical benefit after VSV-hIFNβ-NIS and subsequent immune checkpoint inhibitor (ICI)-based therapy.Twenty-one eligible patients were treated. No dose-limiting toxicities (DLTs) occurred at dose level (DL)1. One grade 3 dehydration event associated with cytokine release syndrome at DL2 prompted revision of the DLT definition; no additional DLTs occurred at DL2 or DL3. One of six patients at DL4 experienced grade 3 delirium meeting DLT criteria. Escalation to DL5 was not feasible because of investigational product volume limitations; therefore, the MTD was not reached. Median age was 65 years, with a median of two prior treatment lines. Treatment-related adverse events were transient hematologic toxicities, liver enzyme elevations, and cytokine release syndrome. Two patients achieved stable disease ≥6 months after VSV-hIFNβ-NIS. Among 15 patients subsequently treated with ICI-containing regimens, four achieved durable stable disease; median overall survival was 20.2 months. Intravenous VSV-hIFNβ-NIS demonstrated an acceptable safety profile, and the MTD was not reached. Durable disease stabilization following subsequent ICI therapy, supports further evaluation of VSV-hIFNβ-NIS

21 June 2026 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
JCJohn J. Coté
John J. Coté
RCRemington D. Coté
Remington D. Coté
KKKeara Kennedy
Keara Kennedy
MBMatthew S. Block
Matthew S. Block
RFRobin Farias-Eisner
Robin Farias-Eisner
LCLesley Conrad
Lesley Conrad